leadf
logo-loader
viewChimeric Therapeutics Ltd
(
ASX:CHM
)

Chimeric Therapeutics announces completion of 28-day follow-up for CLTX Car T Phase 1 trial patient

Chimeric Therapeutics (ASX: CHM) COO Jennifer Chow joined Steve Darling from Proactive to confirm that all patients dosed in the first patient cohort in City of Hope’s phase 1 CLTX CAR T cell clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities.

Chow telling Proactive now that this safety milestone for all patients in cohort 1 has been met, the trial will now advance to the second dosing level, which will administer CLTX CAR T cells by two routes intratumoral and intracranial intraventricular.

Quick facts: Chimeric Therapeutics Ltd

Follow
ASX:CHM

Price: 0.335 AUD

Market Cap: $111.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead...

1 week, 4 days ago

2 min read